Sodium glucose cotransporters inhibitors in type 1 diabetes

Sergio Dellepiane, Moufida Ben Nasr, Emma Assi, Vera Usuelli, Teresa Letizia, Francesca D'Addio, Gian Vincenzo Zuccotti, Paolo Fiorina

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Sodium glucose cotransporter inhibitors (SGLTi) are oral hypoglycemic drugs that reduce renal glucose re-uptake and induce glycosuria. SGLTi have been successfully tested in large randomized clinical trials for type 2 diabetes, and several molecules have been approved in this setting by the international pharmaceutical agencies. Additionally, recent evidence has shown that SGLTi may be useful also in type 1 diabetes (T1D). Indeed, these drugs can be used as an ancillary to insulin to improve glycemic control and reduce insulin dosage, and such regimens have been associated with a lower rate of hypoglycemic episodes. The pharmacological effects of SGLTi therapy are described herein, and we also discuss the future use of SGLTi in T1D.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalPharmacological Research
StatePublished - Jul 2018
Externally publishedYes


  • Diabetic kidney disease
  • Gliflozin
  • SGLT1
  • SGLT2
  • Type 1 diabetes


Dive into the research topics of 'Sodium glucose cotransporters inhibitors in type 1 diabetes'. Together they form a unique fingerprint.

Cite this